InvestorsHub Logo
Followers 5
Posts 280
Boards Moderated 0
Alias Born 08/29/2015

Re: None

Tuesday, 04/25/2017 9:48:11 AM

Tuesday, April 25, 2017 9:48:11 AM

Post# of 459499
Interesting info from Biogen's CC
Have stopped testing of Bib-61 their product that promotes re-myelination, but didn't mention testing of Anavex 2-73 MLA directly.
CEO working on new innovations and " in discussions"
Looking towards early clinical developments for asymmetrical value and are open to something later in development. See value in ODD(orphan drug development)and the intersection of neurological disorders.
GLTA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News